/
Infectious Disease
HIV-1
40
Pipeline Programs↗
49
Active Trials↗
25
Companies Involved↗
HIV-1 is a moderately active landscape with 40 programs across 25 companies. The most active players are Gilead, GSK. 11 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical17
Phase 16
Phase 26
Approved
No programs
Analysis
Modality Breakdown
91%
Small molecule
30 of 33 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 33 classified programs, each share of the total. Modality classified for 88% of 40 pipeline programs.
Analysis
Trial Status
239
clinical trials
Completed149 · 62%
Recruiting21 · 9%
Terminated17 · 7%
Unknown status15 · 6%
Not yet recruiting14 · 6%
Active, not recruiting14 · 6%
Other9 · 4%
Clinical Trials
Trial Activity
239 trials
Page 1 of 16
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)